In contrast to our prediction, RASSF1 promoter hyper methylation was not the most important candidate for thyroid cancer association because higher ORs were observed for CDH1 and SLC5. The trim-and-fill method, which was not performed for RASSF1, implies that there was only very minor publication bias. The gene discussed is RASSF1; the disease is thyroid cancer.